-
Barron's Picks & Pans: Martin Marietta Materials, Deutsche Bank, Mylan And More
Monday, March 7, 2016 - 7:55am | 640Read More...Featured stories in this weekend's Barron's offer a look at the prospects for two building materials companies, a European banking giant and a generic pharmaceuticals maker. A special report features the annual ranking of America's top 1,200 financial advisors by state. Also...
-
Shares Of Mylan Slightly Higher Following Launch Of Generic Drug
Tuesday, December 29, 2015 - 9:56am | 130Read More...Shares of Mylan NV (NASDAQ: MYL) were trading higher by 0.85 percent early Tuesday morning after the company announced the launch of Linezolid Tablets, 600 mg. Linezolid is a generic version of Pfizer Inc. (NYSE: PFE)'s Zyvox Tablets and is intended for adults and children for the treatment...
-
Mylan-Perrigo Buyout Offer: What's Next?
Monday, September 14, 2015 - 11:51am | 276Read More...Mylan NV (NASDAQ: MYL) shares have slipped 13 percent this year, while Perrigo Company plc Ordinary Shares (NYSE: PRGO) shares have gained 8 percent. In an expected move, Mylan offered a combined cash and stock offer of $186.895 for Perrigo, which included $75 in cash and 2.3 Mylan shares...
-
Theravance Just Lost Its Catalyst
Wednesday, September 9, 2015 - 1:45pm | 490Read More...Shares of Theravance Inc (NASDAQ: THRX) fell more than 12 percent Wednesday morning after the company's commercial partner, GlaxoSmithKline plc (ADR) (NYSE: GSK), disclosed topline results from SUMMIT. Theravance's trial attempted to prove survival benefits for Breo in COPD patients and failed to...
-
Is Mylan's FDA Warning Letter Worth Worrying About?
Tuesday, August 18, 2015 - 2:33pm | 331Read More...Mylan NV (NASDAQ: MYL) commented publicly for the first time to a FDA warning letter which it received on August 6, relating to its Agila Specialty Formulation Facility (SFF), Sterile Product Division (SPD), and Onco Therapies Limited (OTL) sites in India. In a press release, Mylan's CEO...
-
Report: Mylan Could See Sweetened Bid From Teva Pharmaceutical
Wednesday, May 27, 2015 - 3:55pm | 262Read More...Teva Pharmaceutical Industries Ltd (NYSE: TEVA) will soon sweeten its $40 billion bid for Netherlands-based Mylan Inc (NASDAQ: MYL) and may resort to Dutch courts if the offer gets rejected, according to a report Wednesday. Mylan changed hands recently up about 1.7 percent at $71.72. Teva may...
-
What's Gabelli Saying About Teva Now?
Wednesday, April 22, 2015 - 11:51am | 319Read More...In a report published Wednesday, Gabelli & Company analyst Kevin Kedra commented on Teva Pharmaceutical Industries Ltd (NYSE: TEVA)'s offer to acquire Mylan NV (NASDAQ: MYL) for $82 per share. Teva argued that the acquisition could realize $2 billion of synergies, resulting in $10 billion...
-
And The Winner From The Mylan-Perrigo Merger Is... Teva?
Thursday, April 9, 2015 - 9:16am | 270Read More...In a report published Wednesday, Citigroup analyst Liav Abraham commented on a Mylan NV (NASDAQ: MYL) and Perrigo Company plc (NYSE: PRGO) combination, noting that a bid from Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) is still possible, but challenging. According to Abraham, if Teva is...
-
JPMorgan Says Mylan Has 3 Paths To Upside
Wednesday, April 8, 2015 - 11:04am | 420Read More...In a report published Wednesday, JPMorgan analyst Chris Schott shared his thoughts on Mylan NV (NASDAQ: MYL). According to Schott, Mylan shares are showing an "increasingly attractive" set-up with solid organic growth prospects (12 percent earnings per share compounded annual growth...
-
S&P 500 Falls To Two-Month Low, Dow Drifts Further Away From The 17,000 Mark
Thursday, August 7, 2014 - 4:41pm | 2840Read More...U.S. stocks declined, following Europe's lead following the European Central Bank's decision to keep interest rates unchanged. The ECB's President Mario Draghi reaffirmed the bank's intention of considering "unconventional moves," which includes buying asset-backed...
-
5 Drug Companies Profiting From Generics
Monday, August 4, 2014 - 8:29am | 864Read More...Leading generic drug maker Teva Pharmaceutical (NYSE: TEVA) posted better than expected earnings last week and raised its full-year profit forecast. There was plenty for investors to be concerned about, though. Sales of its best-selling product, Copaxone, were down for the quarter, and activist...
-
Dow Sets New Intraday High; Citigroup Impresses With Earnings
Monday, July 14, 2014 - 4:44pm | 2632Read More...U.S. stocks rose as earning season unofficially kicked off with Citigroup reporting better than expected earnings. The Dow Jones Industrial average set new intra-day records, hitting an all time high of 17,088.43 as investors appear to be comfortable with holding blue chips instead of...
-
Earnings Expectations For The Week Of April 28: Big Oil, Big Pharma And More
Sunday, April 27, 2014 - 11:58am | 854Read More...The earnings crunch continues this week. Among the highlights will be scheduled quarterly reports from Exxon Mobil and Chevron, from Bristol-Myers Squibb and Merck, from Time Warner and Viacom, and also from Twitter. Early Thursday, Exxon Mobil (NYSE: XOM) is expected to say that it had earnings...
-
Market Wrap For April 4: Dow Suffers Triple Digit Point Loss, Nasdaq Continues To Underperform
Friday, April 4, 2014 - 4:44pm | 2444Read More...U.S. stocks ended the week on a sour note as investors continue to sell many momentum names. Not helping the bull case was the much anticipated Jobs report number which failed to "wow" the market, coming in relatively in-line with expectations. The Dow suffered a triple digit point loss and...
-
Pfizer's Blockbuster Drug Celebrex To Lose Patent Protection
Thursday, March 13, 2014 - 11:21am | 474Read More...In the pharmaceutical and biotech space, giant moves in a company’s stock isn’t exactly news and in this case a decline of 1.4 percent shouldn’t be much of a story...but when the company is Pfizer (NYSE: PFE), a 1.4 percent loss means something big probably happened. And it did. Wednesday, a U....
